APA (7th ed.) Citation

Galsky, M. D., Arija, J. Á. A., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E., . . . Vogelzang, N. J. (2020). Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 395(10236), 1547. https://doi.org/10.1016/S0140-6736(20)30230-0

Chicago Style (17th ed.) Citation

Galsky, Matthew D., et al. "Atezolizumab with or Without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo-controlled Phase 3 Trial." Lancet 395, no. 10236 (2020): 1547. https://doi.org/10.1016/S0140-6736(20)30230-0.

MLA (9th ed.) Citation

Galsky, Matthew D., et al. "Atezolizumab with or Without Chemotherapy in Metastatic Urothelial Cancer (IMvigor130): A Multicentre, Randomised, Placebo-controlled Phase 3 Trial." Lancet, vol. 395, no. 10236, 2020, p. 1547, https://doi.org/10.1016/S0140-6736(20)30230-0.